Epizyme, Inc. (NASDAQ:EPZM) insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction on Monday, July 24th. The stock was sold at an average price of $13.44, for a total value of $201,600.00. Following the sale, the insider now owns 22,228 shares in the company, valued at $298,744.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Peter Tai-Ching Ho also recently made the following trade(s):

  • On Monday, June 26th, Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock. The stock was sold at an average price of $14.87, for a total value of $223,050.00.
  • On Thursday, May 25th, Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock. The stock was sold at an average price of $16.11, for a total value of $241,650.00.

Shares of Epizyme, Inc. (NASDAQ:EPZM) traded down 2.77% during midday trading on Wednesday, reaching $12.30. The company had a trading volume of 333,671 shares. Epizyme, Inc. has a 1-year low of $7.02 and a 1-year high of $18.50. The stock’s market capitalization is $717.80 million. The company’s 50-day moving average is $13.81 and its 200-day moving average is $14.29.

Epizyme (NASDAQ:EPZM) last posted its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.07. Epizyme had a negative return on equity of 55.41% and a negative net margin of 1,376.33%. On average, equities research analysts forecast that Epizyme, Inc. will post ($2.42) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/26/peter-tai-ching-ho-sells-15000-shares-of-epizyme-inc-epzm-stock-2.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of EPZM. Legal & General Group Plc increased its position in Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares in the last quarter. UBS Asset Management Americas Inc. purchased a new position in Epizyme during the first quarter worth $175,000. Bank of America Corp DE increased its position in Epizyme by 45.4% in the first quarter. Bank of America Corp DE now owns 14,561 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 4,544 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in Epizyme during the fourth quarter worth $351,000. Finally, Metropolitan Life Insurance Co. NY increased its position in Epizyme by 11.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 30,680 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 3,269 shares in the last quarter. 81.63% of the stock is currently owned by institutional investors.

EPZM has been the topic of a number of recent analyst reports. Oppenheimer Holdings, Inc. set a $26.00 target price on Epizyme and gave the stock a “buy” rating in a research note on Monday, June 5th. Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Tuesday, May 16th. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Epizyme in a research note on Wednesday, June 7th. CIBC reiterated an “outperform” rating on shares of Epizyme in a research note on Thursday, April 13th. Finally, Royal Bank Of Canada set a $20.00 target price on Epizyme and gave the stock a “buy” rating in a research note on Monday, June 12th. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $23.75.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Insider Buying and Selling by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.